Neurocrine Biosciences Inc (NBIX) · Sep 28, 2026 · Exec change

Neurocrine replaces CMO Keswani with former chief Roberts amid pipeline expansion

CMO departure — Keswani out September 25; Roberts effective September 28

Neurocrine abruptly ends its CMO’s tenure and reinstates former chief Eiry Roberts, limiting disruption but raising a leadership-transition flag.

Neurocrine is a commercial-stage neuroscience and endocrine biotech, led by INGREZZA and CRENESSITY while expanding a mid- to late-stage pipeline and integrating the Soleno acquisition. The abrupt CMO change is a real leadership disruption, not routine succession. The company says Sanjay Keswani’s service ended by mutual agreement on September 25, only about 15 months after he took over the role, before Eiry Roberts was appointed effective September 28. 〔0〕

Roberts’ return cushions the operational risk. She previously served as Neurocrine’s CMO for seven years before moving into a strategic-advisor role, so the company is restoring an experienced internal leader rather than searching externally. That continuity matters while Neurocrine is advancing multiple clinical programs and broadening its commercial portfolio. The signal is still mixed because the filing gives no reason for Keswani’s departure. It also commits to severance for him and a new compensation package for Roberts, including an $825,000 salary and approximately $1.25 million of target equity grants, creating incremental cost but not a material capital event. 〔1〕

Bottom line: This is a meaningful management reset in a key R&D role, but the return of a proven former CMO limits the risk of a prolonged transition. The business story is therefore more complicated than impaired: disruption is evident, while continuity is preserved.

What to watch next

Amended employment agreement in the next quarterly 10-Q

Original filing on SEC EDGAR

More Neurocrine Biosciences Inc news

Neurocrine replaces CMO Keswani with former chief Roberts amid pipeline expansion | NBIX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.